Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.42 |
| ▸ | CCR2 | P41597 | 4/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5033733 | 0.91 | CNR2 (0.45) | RAB9AP2RY12CCR2LIPGCNR2 | |
| SCHEMBL5029445 | 0.81 | CTSA (0.45) | RAB9ACCR2LIPGCNR2USP30 | |
| SCHEMBL5029439 | 0.81 | CTSA (0.45) | RAB9ACCR2LIPGCNR2USP30 | |
| SCHEMBL5033653 | 0.81 | CCR2 (0.51) | RAB9ACCR2NPC1SMYD3 | |
| SCHEMBL5033656 | 0.81 | CCR2 (0.51) | RAB9ACCR2NPC1SMYD3 | |
| SCHEMBL5030274 | 0.81 | RAB9A (0.46) | RAB9ACCR2NPC1SMYD3 | |
| SCHEMBL5030277 | 0.81 | RAB9A (0.46) | RAB9ACCR2NPC1SMYD3 | |
| SCHEMBL5027275 | 0.79 | ALDH1A1 (0.56) | RAB9ACCR2CNR2NPC1 | |
| SCHEMBL5027265 | 0.79 | ALDH1A1 (0.56) | RAB9ACCR2CNR2NPC1 | |
| SCHEMBL5031756 | 0.74 | RAB9A (0.40) | RAB9ACCR2NPC1SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | RAB9A 2580/4885P2RY12 2345/4885CCR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.